Hu K S, Harrison L B
Department of Radiation Oncology, Beth Israel Medical Center, New York, New York, USA.
Semin Surg Oncol. 2000 Dec;19(4):336-49. doi: 10.1002/ssu.4.
The mainstay of treatment for rectal cancer over the past 100 years has been surgical resection. However, for the majority of rectal cancers treated conventionally by resection alone, locoregional recurrence is the major mode of failure. Over the past several decades, significant progress has been made in developing effective adjuvant regimens. In the United States, postoperative chemoradiation is standard treatment for T3 or node-positive patients. However, preoperative radiation with or without chemotherapy decreases local recurrence, increases sphincter preservation, and may improve survival. The purpose of this article is to review the role of adjuvant therapy in resectable rectal cancers and to update the status of ongoing randomized trials.
在过去的100年里，直肠癌治疗的主要方法一直是手术切除。然而，对于大多数仅通过手术进行传统治疗的直肠癌患者来说，局部区域复发是主要的失败模式。在过去几十年中，在开发有效的辅助治疗方案方面取得了重大进展。在美国，术后放化疗是T3期或淋巴结阳性患者的标准治疗方法。然而，术前放疗加或不加化疗可降低局部复发率，增加括约肌保留率，并可能提高生存率。本文的目的是综述辅助治疗在可切除直肠癌中的作用，并更新正在进行的随机试验的现状。
